P21-Adamantane: Scientific Profile

Publicado el 12 de julio de 2026 · Actualizado el 17 de julio de 2026

P21-Adamantane (P021, CAS 1246751-68-7) is an adamantylated neurotrophic tetrapeptide derived from the active region of ciliary neurotrophic factor (CNTF), designed for research in neurogenesis and synaptic plasticity. Its proposed mechanism involves the stimulation of neurotrophic factors (BDNF) and the reduction of tau hyperphosphorylation. Compound exclusively for research use.

P21-Adamantane, known in the literature as P021 or Peptide 021 (CAS 1246751-68-7; molecular formula C27H42N6O8; molecular weight 578.67 g/mol), is a small peptidergic compound classified within the category of experimental nootropics. It is a tetrapeptide acetylated at the N-terminus and modified with an adamantane group (adamantylation) at the C-terminus. This molecular architecture does not correspond to a conventional linear peptide, but rather to a chemically optimized derivative designed to improve metabolic stability and the ability to cross the blood-brain barrier in research models.

The origin of P021 traces back to work on the active region of ciliary neurotrophic factor (CNTF, ciliary neurotrophic factor). Researchers in the field of neurochemistry identified an eleven-residue peptide fragment, referred to in the literature as "Peptide 6", corresponding to a biologically active region of human CNTF. From that fragment, a progressive structural simplification was carried out down to a minimal tetrapeptide core (with the central sequence Asp-Gly-Gly-Leu, Ac-DGGL), to which the adamantane group was added to confer lipophilicity, resistance to degradation by peptidases, and penetration into the central nervous system. The result is a low-molecular-weight molecule conceived as a research tool in preclinical neuroscience.

Regarding structure, the combination of an acetylated terminus, a short tetrapeptide backbone, and the bulky hydrocarbon cage of adamantane defines its physicochemical properties: it is more lipophilic and stable than the native peptide from which it derives, characteristics that in animal models have been associated with better central bioavailability. The formula C27H42N6O8 precisely reflects this hybridization between a polar peptide motif and a nonpolar hydrocarbon fragment.

The proposed mechanism of action for P021 is multifaceted and has been studied mainly in in vitro models and in rodents. The central hypothesis is that the compound acts as a neurotrophic mimetic: instead of administering complete neurotrophic factors (which are large proteins with poor brain penetration), P021 would seek to reproduce part of their signaling through a small and stable fragment. In the preclinical studies published by the group that developed it, exposure to P021 has been associated with an increase in the expression of brain-derived neurotrophic factor (BDNF) and with the potentiation of synaptic plasticity pathways, as well as with the stimulation of neurogenesis in the dentate gyrus of the hippocampus. Another mechanistic line explored is the modulation of signaling mediated by leukemia inhibitory factor (LIF) and by CNTF, receptors that share transduction components. Additionally, in tauopathy models a reduction of the hyperphosphorylation of the tau protein has been observed, an effect that some authors relate to the modulation of kinases such as GSK-3β and to the restoration of phosphatase activity. It is important to emphasize that these mechanisms represent working hypotheses supported by preclinical data and do not constitute clinically confirmed effects.

The documented research applications are concentrated in the field of neurodegeneration and cognitive decline. P021 has been investigated in murine models of Alzheimer's disease (both amyloid pathology and tau pathology), in Down syndrome models, and in cognitive aging paradigms. The outcomes evaluated in those studies include dendritic spine density, neurogenesis markers, tau phosphorylation levels, and performance in behavioral memory tests in animals. It has also been used as a tool to study the relationship between neurotrophic factor deficits and synaptic dysfunction. All these applications correspond strictly to laboratory and basic research contexts; none represents an established therapeutic use.

Regarding the level of evidence, it is essential to be honest and prudent. P021 has a reasonably consistent body of preclinical work, generated in large part by the research group that designed it and by collaborators. There is, as far as the generally accessible literature reaches, no clinical evidence in humans of efficacy or safety, nor regulatory approvals supporting medical use. The compound must therefore be considered a candidate in the preclinical research phase and not a drug. Broad independent replication remains limited, so conclusions about its activity must be interpreted with caution. Any extrapolation of the animal results to a clinical benefit would be speculative and is not justified by the available data.

In summary, P21-Adamantane is a small peptide molecule, chemically optimized through acetylation and adamantylation, conceived as a neurotrophic mimetic for the study of neurogenesis, synaptic plasticity, and tau pathology in experimental models. Its interest lies in the possibility of investigating, with a stable and penetrant tool, mechanisms that until now depended on large proteins that are difficult to administer. However, its evidence profile remains in the preclinical realm, and in this catalog it is offered exclusively as material intended for scientific laboratory research.